Form 4: Kiniksa Pharmaceuticals COO Executes Pre-Planned Stock Transactions, Reducing Direct Shareholding

Kiniksa Pharmaceuticals International, plc's Chief Operating Officer, Eben Tessari, engaged in pre-planned stock transactions, exercising options and selling a portion of Class A Ordinary Shares.

Summary

• Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported transactions involving the company's Class A Ordinary Shares.
• On June 16, 2025, Mr. Tessari acquired 6,500 Class A Ordinary Shares through the exercise of stock options at a price of $8.83 per share.
• Concurrently, Mr. Tessari disposed of 17,300 Class A Ordinary Shares at a weighted average sales price of $28.28 per share, with individual trades ranging from $27.795 to $28.645.
• Both transactions were executed pursuant to a Rule 10b5-1 trading plan established by Mr. Tessari on April 29, 2024.
• Following these transactions, Mr. Tessari's direct beneficial ownership of Class A Ordinary Shares decreased to 61,563 shares.
• Mr. Tessari also holds 38,500 share options, which are fully vested and exercisable, with an exercise price of $8.83 and an expiration date of September 16, 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there was a net sale of shares by an insider, the transaction was pre-planned under a 10b5-1 plan, which typically mitigates negative interpretations. The exercise of options also indicates the insider realizing value from their equity.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to personal financial management rather than a reaction to immediate company news.
• The Chief Operating Officer exercised options, demonstrating engagement and realizing value from previously granted equity.

Negatives

• The Chief Operating Officer's direct beneficial ownership of Class A Ordinary Shares decreased by a net of 10,800 shares (17,300 sold minus 6,500 acquired), which could be interpreted by some investors as a reduction in insider exposure.

Future Outlook

This SEC Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The reported transactions were effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends for the pharmaceutical sector.

Stakeholder Impact

• Shareholders: May interpret the net reduction in direct ownership by a key executive differently; however, the 10b5-1 plan context suggests a pre-planned financial move rather than a signal about company prospects.

Key Dates

Keywords

Kiniksa Pharmaceuticals, KNSA, SEC Form 4, Insider Trading, Stock Options, Share Sale, Eben Tessari, Chief Operating Officer, 10b5-1 Plan, Equity Compensation